Annals of internal medicine
-
Comment Randomized Controlled Trial
In knee OA, PT vs. glucocorticoid injections had an incremental cost-effectiveness ratio of $35 527/QALY gained.
Rhon DI, Kim M, Asche CV, et al. Cost-effectiveness of physical therapy vs intra-articular glucocorticoid injection for knee osteoarthritis: a secondary analysis from a randomized clinical trial. JAMA Netw Open. 2022;5:e2142709. 35072722.
-
Comment Randomized Controlled Trial
In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.
Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10:327-36. 35123660.
-
Randomized Controlled Trial
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.
Frailty may modify the risk-benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments. ⋯ AstraZeneca.
-
Comment Randomized Controlled Trial
In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327:138-50. 35015037.
-
Comment Randomized Controlled Trial
In adults hospitalized with COVID-19, adding remdesivir to standard care did not reduce in-hospital mortality.
Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194:E242-51. 35045989.